top of page
TEAM
STEPHEN BERGE, Ph.D.
TOM BURKE
PHILIP CHAIKIN, PharmD., MD, F.C.P.
STEVE ELROD, Ph.D., DABT
MARK ROBBINS, Ph.D., J.D.
SERVICES
FUNDRAISING AND INVESTMENT
BUSINESS PLAN DEVELOPMENT
DRUG COMMERCIALIZATION
DRUG DEVELOPMENT
LITIGATION SUPPORT SERVICES
REGULATORY SERVICES
CONTACT
NEWS
More
Use tab to navigate through the menu items.
PATENT PHARMA DAMAGES AFTER AN AT-RISK LAUNCH: A REAL WORLD APPROACH
Robins • Kaplan Webinar Series: PATENT PHARMA DAMAGES AFTER AN AT-RISK LAUNCH: A REAL WORLD APPROACH_DOWNLOAD
Featured Articles
PATENT PHARMA DAMAGES AFTER AN AT-RISK LAUNCH: A REAL WORLD APPROACH
A lecture at the University of MN College of Pharmacy, presented by Mark S. Robbins on April 11, 201
The Bial 10-2474 Phase 1 Study— A Drug Development Perspective and Recommendations for Future First-
Life Sciences: The isolated human umbilical vein as a bioassay for kinin-generating proteases: An in
Recent Articles
Successful Outcome in Contract Litigation
PATENT PHARMA DAMAGES AFTER AN AT-RISK LAUNCH: A REAL WORLD APPROACH
A lecture at the University of MN College of Pharmacy, presented by Mark S. Robbins on April 11, 201
The Bial 10-2474 Phase 1 Study— A Drug Development Perspective and Recommendations for Future First-
Life Sciences: The isolated human umbilical vein as a bioassay for kinin-generating proteases: An in
Pharmacological effects of recombinant human tissue kallikrein on bradykinin B2 receptors
Archive
September 2024
(1)
1 post
July 2018
(1)
1 post
April 2018
(1)
1 post
January 2018
(3)
3 posts
Search By Tags
No tags yet.
Follow Us
bottom of page